Healthcare › Medical Devices
Medtronic
- Ticker
- MDT
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical Devices
Price data arrives in a later stage, so no price is shown yet.
Latest news
ImportantMDT
Explain this story: Is Medtronic (MDT) Reasonable On Cash Flow After Its $700 Million Robotics Bet?
Medtronic (MDT) shares have returned 25.2% over the past three years, prompting a review of whether its current share price aligns with its expected cash flows. Despite recent regulatory milestones and a $700 million robotics partnership, the stock's valuation, based on a Discounted Cash Flow (DCF) model, suggests it is meaningfully undervalued compared to its current price of $86.44. The DCF model indicates future cash flows support a higher intrinsic worth, with the upfront cost of the robotics partnership partially explaining the current price lag.
OtherSimply Wall StreetSector and industry: HealthcareMedical DevicesTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Medtronic (MDT) shares have returned 25.2% over the past three years, prompting a review of whether its current share price aligns with its expected cash flows. Despite recent regulatory milestones and a $700 million robotics partnership, the stock's valuation, based on a Discounted Cash Flow (DCF) model, suggests it is meaningfully undervalued compared to its current price of $86.44. The DCF model indicates future cash flows support a higher intrinsic worth, with the upfront cost of the robotics partnership partially explaining the current price lag.
ImportantMDT
Explain this story: Medtronic drug-coated balloon gets FDA breakthrough status
Medtronic has received FDA breakthrough device designation for its drug-coated balloon catheter designed to treat peripheral artery disease (PAD) below the knee. This is a significant development as current drug-coated balloons are not indicated for use in this area, which is historically difficult to treat and can lead to amputation. Medtronic plans a randomized pivotal trial with approximately 400 patients to study the effectiveness of its IN.PACT BTK paclitaxel-coated device.
Other
Company newsMDT
Explain this story: Medtronic reveals cardiac mapping and ablation software clearances
Medtronic announced it has received regulatory clearances for new cardiac mapping and ablation software in both the U.S. and Europe. The clearances are for its Affera Prism-2 Mapping Software and a CE mark for the PulseSelect ProxBox Adapter with Proximity Indicator software, aiming to enhance the company's position in the competitive pulsed field ablation market. These software advancements are designed to provide physicians with better visualization and real-time feedback during cardiac ablation procedures.
OtherMedTech DiveHealthcare
Elsewhere
These links open other websites. We do not provide price data yet.